↓ Skip to main content

Dove Medical Press

High-dose amikacin for achieving serum target levels in critically ill elderly patients

Overview of attention for article published in Infection and Drug Resistance, February 2018
Altmetric Badge

About this Attention Score

  • In the top 25% of all research outputs scored by Altmetric
  • Good Attention Score compared to outputs of the same age (79th percentile)
  • High Attention Score compared to outputs of the same age and source (89th percentile)

Mentioned by

twitter
13 X users

Citations

dimensions_citation
20 Dimensions

Readers on

mendeley
36 Mendeley
Title
High-dose amikacin for achieving serum target levels in critically ill elderly patients
Published in
Infection and Drug Resistance, February 2018
DOI 10.2147/idr.s150839
Pubmed ID
Authors

Kourosh Sadeghi, Hadi Hamishehkar, Farhad Najmeddin, Arezoo Ahmadi, Ebrahim Hazrati, Hooshyar Honarmand, Mojtaba Mojtahedzadeh

Abstract

To achieve target concentrations, the application of higher-than-standard doses of amikacin is proposed for the treatment of sepsis due to an increase in volume of distribution and clearance, but little data are available on aminoglycoside administration in critically ill elderly patients. Forty critically ill elderly patients (aged over 65 years) who required amikacin therapy due to severe documented, or suspected gram-negative infections, were randomly assigned to two treatment groups. Group A (20 patients) received 15 mg/kg amikacin and Group B (20 patients) received 25 mg/kg amikacin per day as a single daily dose. All the patients were monitored for renal damage by the daily monitoring of serum creatinine. The amikacin peak (Cmax) and trough (Cmin) serum concentrations were measured on Days 3 and 7 postadministration. Data from 18 patients in Group A and 15 patients in Group B were finally analyzed. On Day 3, the amikacin mean Cmaxlevels in the standard and high-dose treatment groups were 30.4±11 and 52.3±16.1 µg/mL (P<0.001), and the Cminlevels were 3.2±2.1 and 5.2±2.8 µg/mL, respectively (P=0.035). On Day 7, the Cmaxlevels in the standard and high-dose groups were 33±7.3 and 60.0±17.6 µg/mL (P=0.001), and the Cminlevels were 3.2±2.9 and 9.3±5.6 µg/mL, respectively (P=0.002). In only six (40%) of the patients in the high-dose groups and none of the patients in the standard-dose group, amikacin Cmaxreached the target levels (>64 µg/mL), whereas the amikacin mean Cminlevels in the high-dose group were above the threshold of toxicity (5 µg/mL). Our results suggest that the optimum dose of amikacin should be determined for elderly critically ill patients. It seems that higher-than-standard doses of amikacin with more extended intervals might be more appropriate than standard once-daily dosing in the elderly critically ill patients.

X Demographics

X Demographics

The data shown below were collected from the profiles of 13 X users who shared this research output. Click here to find out more about how the information was compiled.
Mendeley readers

Mendeley readers

The data shown below were compiled from readership statistics for 36 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
Unknown 36 100%

Demographic breakdown

Readers by professional status Count As %
Student > Bachelor 5 14%
Student > Master 5 14%
Researcher 5 14%
Other 4 11%
Student > Ph. D. Student 1 3%
Other 3 8%
Unknown 13 36%
Readers by discipline Count As %
Pharmacology, Toxicology and Pharmaceutical Science 9 25%
Medicine and Dentistry 5 14%
Agricultural and Biological Sciences 2 6%
Nursing and Health Professions 1 3%
Business, Management and Accounting 1 3%
Other 5 14%
Unknown 13 36%
Attention Score in Context

Attention Score in Context

This research output has an Altmetric Attention Score of 8. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 06 December 2018.
All research outputs
#3,944,264
of 23,025,074 outputs
Outputs from Infection and Drug Resistance
#132
of 1,686 outputs
Outputs of similar age
#87,999
of 440,124 outputs
Outputs of similar age from Infection and Drug Resistance
#4
of 37 outputs
Altmetric has tracked 23,025,074 research outputs across all sources so far. Compared to these this one has done well and is in the 82nd percentile: it's in the top 25% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 1,686 research outputs from this source. They receive a mean Attention Score of 3.8. This one has done particularly well, scoring higher than 92% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 440,124 tracked outputs that were published within six weeks on either side of this one in any source. This one has done well, scoring higher than 79% of its contemporaries.
We're also able to compare this research output to 37 others from the same source and published within six weeks on either side of this one. This one has done well, scoring higher than 89% of its contemporaries.